MHP1-AcN

MHP1-AcN (Microglia Healing Peptide 1 with N-terminal acetylation and C-terminal amidation) is a modified peptide derived from the receptor activator of nuclear factor-kappa B ligand (RANKL). It lacks the osteoclast-activating CD loop of RANKL but retains the ability to bind to key receptors. MHP1-AcN acts as a multi-pathway modulator with anti-inflammatory, anti-osteoclastic, and anti-fibrotic properties. It directly binds to RANK, TNFR1 (TNF receptor 1), CD14, and LGR4 (leucine-rich repeat-containing G protein-coupled receptor 4). By binding to LGR4, it acts as an antagonist that disrupts the RSPO3-LGR4-IQGAP1 signaling complex, thereby suppressing Wnt/beta-catenin signaling. It also inhibits TLR-mediated inflammatory cascades (including TLR2, TLR3, TLR4, and TLR9) and suppresses TGF-beta/Smad signaling. MHP1-AcN is being investigated in preclinical models for the treatment of osteoarthritis, osteoporosis, psoriasis, pulmonary fibrosis, and lung adenocarcinoma.

Other names

MHP1MHP-1MHP 1Microglia Healing Peptide 1 with N-terminal acetylation and C-terminal amidationMicroglial healing peptide 1 with N-terminal acetylation and C-terminal amidation